{"transactions":[{"id":2390062,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":124124,"kind":"person","name":"Pierce Robert Hamilton","position":1,"cik":"0001594129","reported_name":"Pierce Robert Hamilton","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief R&D Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-17T23:23:17.000Z","date":"2022-02-15","kind":"grant","acquired":true,"shares":62000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 15, 2023; and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date."}],"balance_after":62000,"derivative":{"exercise_price":4.3,"expiration_date":"2032-02-14","underlying":"Common Stock","underlying_shares":62000},"source":{"system":"sec-edgar","filing":"0001209191-22-010982","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000120919122010982/doc4.xml","form_type":"4"}},{"id":2390061,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":124124,"kind":"person","name":"Pierce Robert Hamilton","position":1,"cik":"0001594129","reported_name":"Pierce Robert Hamilton","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief R&D Officer"}}],"security":"Common Stock","published_at":"2022-02-17T23:23:17.000Z","date":"2022-02-15","kind":"grant","acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (the \"RSUs\"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in four equal annual installments on each of February 15, 2023, February 15, 2024, February 15, 2025 and February 15, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such date."}],"balance_after":21000,"source":{"system":"sec-edgar","filing":"0001209191-22-010982","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000120919122010982/doc4.xml","form_type":"4"}},{"id":2606058,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":124124,"kind":"person","name":"Pierce Robert Hamilton","position":1,"cik":"0001594129","reported_name":"Pierce Robert Hamilton","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-08-12T21:07:30.000Z","date":"2021-08-11","kind":"sale","acquired":false,"shares":16030,"price":7.3436,"value":117717.908,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.10 to $7.81, inclusive. The reporting person undertakes to provide to Sensei Biotherapeutics, Inc., any security holder of Sensei Biotherapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-051172","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000120919121051172/doc4.xml","form_type":"4"}},{"id":2609316,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":124124,"kind":"person","name":"Pierce Robert Hamilton","position":1,"cik":"0001594129","reported_name":"Pierce Robert Hamilton","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-08-10T21:40:54.000Z","date":"2021-08-10","kind":"sale","acquired":false,"shares":66350,"price":7.1289,"value":473002.515,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.00 to $7.42, inclusive."}],"balance_after":16030,"source":{"system":"sec-edgar","filing":"0001209191-21-050659","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000120919121050659/doc4.xml","form_type":"4"}},{"id":2609315,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":124124,"kind":"person","name":"Pierce Robert Hamilton","position":1,"cik":"0001594129","reported_name":"Pierce Robert Hamilton","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-08-10T21:40:54.000Z","date":"2021-08-09","kind":"sale","acquired":false,"shares":6982,"price":7.0603,"value":49295.0146,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.00 to $7.10, inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."}],"balance_after":82380,"source":{"system":"sec-edgar","filing":"0001209191-21-050659","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000120919121050659/doc4.xml","form_type":"4"}},{"id":2609314,"issuer":{"id":5029,"kind":"organization","name":"Faeth Therapeutics, Inc.","symbol":"FTH"},"owners":[{"id":124124,"kind":"person","name":"Pierce Robert Hamilton","position":1,"cik":"0001594129","reported_name":"Pierce Robert Hamilton","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-08-10T21:40:54.000Z","date":"2021-08-06","kind":"sale","acquired":false,"shares":6460,"price":7.1127,"value":45948.042,"ownership":{"direct":false,"nature":"By spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.04 to $7.20, inclusive. The reporting person undertakes to provide to Sensei Biotherapeutics, Inc., any security holder of Sensei Biotherapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (3) and (4) to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose."}],"balance_after":89362,"source":{"system":"sec-edgar","filing":"0001209191-21-050659","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1829802/000120919121050659/doc4.xml","form_type":"4"}}]}